ID   CDK12_HUMAN             Reviewed;        1490 AA.
AC   Q9NYV4; A7E2B2; B4DYX4; B9EIQ6; O94978;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 2.
DT   12-OCT-2022, entry version 199.
DE   RecName: Full=Cyclin-dependent kinase 12;
DE            EC=2.7.11.22;
DE            EC=2.7.11.23 {ECO:0000305|PubMed:20952539};
DE   AltName: Full=Cdc2-related kinase, arginine/serine-rich;
DE            Short=CrkRS;
DE   AltName: Full=Cell division cycle 2-related protein kinase 7;
DE            Short=CDC2-related protein kinase 7;
DE   AltName: Full=Cell division protein kinase 12;
DE            Short=hCDK12;
GN   Name=CDK12; Synonyms=CRK7, CRKRS, KIAA0904;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND FUNCTION.
RX   PubMed=11683387; DOI=10.1242/jcs.114.14.2591;
RA   Ko T.K., Kelly E., Pines J.;
RT   "CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with
RT   SC35 speckles.";
RL   J. Cell Sci. 114:2591-2603(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 5:355-364(1998).
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-681 AND SER-685, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-57; TYR-73; SER-400; SER-423;
RP   THR-514; SER-681; SER-685 AND THR-692, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; SER-301; SER-303;
RP   SER-318; SER-323; SER-325; SER-332; SER-333; SER-334; SER-345; SER-383;
RP   SER-385; SER-400; SER-681; SER-685 AND THR-692, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   FUNCTION.
RX   PubMed=19651820; DOI=10.1093/carcin/bgp187;
RA   Iorns E., Martens-de Kemp S.R., Lord C.J., Ashworth A.;
RT   "CRK7 modifies the MAPK pathway and influences the response to endocrine
RT   therapy.";
RL   Carcinogenesis 30:1696-1701(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-420; SER-423; SER-681;
RP   SER-685; THR-692 AND SER-1053, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-383; SER-385;
RP   SER-681; SER-685 AND THR-1244, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20952539; DOI=10.1101/gad.1968210;
RA   Bartkowiak B., Liu P., Phatnani H.P., Fuda N.J., Cooper J.J., Price D.H.,
RA   Adelman K., Lis J.T., Greenleaf A.L.;
RT   "CDK12 is a transcription elongation-associated CTD kinase, the metazoan
RT   ortholog of yeast Ctk1.";
RL   Genes Dev. 24:2303-2316(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-385;
RP   SER-400; SER-423; SER-681; SER-685; THR-893 AND SER-1083, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   CHROMOSOMAL REARRANGEMENT WITH ERBB2, AND POSSIBLE INVOLVEMENT IN GASTRIC
RP   CANCER.
RX   PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749;
RA   Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D.,
RA   Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H.,
RA   Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.;
RT   "Genetic and structural variation in the gastric cancer kinome revealed
RT   through targeted deep sequencing.";
RL   Cancer Res. 71:29-39(2011).
RN   [20]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=22012619; DOI=10.1101/gad.16962311;
RA   Blazek D., Kohoutek J., Bartholomeeusen K., Johansen E., Hulinkova P.,
RA   Luo Z., Cimermancic P., Ule J., Peterlin B.M.;
RT   "The Cyclin K/Cdk12 complex maintains genomic stability via regulation of
RT   expression of DNA damage response genes.";
RL   Genes Dev. 25:2158-2172(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-274;
RP   SER-276; SER-301; SER-303; SER-310; SER-312; SER-332; SER-333; SER-334;
RP   SER-338; SER-423; SER-681; SER-685; THR-893 AND SER-1083, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-265;
RP   SER-274; SER-276; SER-318; SER-323; SER-325; SER-332; SER-333; SER-334;
RP   SER-341; SER-343; SER-345; SER-423; THR-514; SER-614; SER-681; THR-692;
RP   SER-889; THR-893; SER-1053 AND SER-1083, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-423; SER-681 AND SER-685, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-263; LYS-509 AND LYS-655, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [25]
RP   INTERACTION WITH HHV-1 TRANSCRIPTIONAL REGULATOR ICP22 (MICROBIAL
RP   INFECTION).
RX   PubMed=34696162; DOI=10.3390/vaccines9101054;
RA   Isa N.F., Bensaude O., Aziz N.C., Murphy S.;
RT   "HSV-1 ICP22 Is a Selective Viral Repressor of Cellular RNA Polymerase II-
RT   Mediated Transcription Elongation.";
RL   Vaccines (Basel) 9:0-0(2021).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 714-1063 IN COMPLEX WITH THE ATP
RP   ANALOG ADP; TRANSITION STATE ANALOG AND CCNK, FUNCTION, CATALYTIC ACTIVITY,
RP   SUBUNIT, INTERACTION WITH CCNK, PHOSPHORYLATION AT THR-893, IDENTIFICATION
RP   BY MASS SPECTROMETRY, MUTAGENESIS OF ASP-877, AND ACTIVITY REGULATION.
RX   PubMed=24662513; DOI=10.1038/ncomms4505;
RA   Boesken C.A., Farnung L., Hintermair C., Merzel Schachter M.,
RA   Vogel-Bachmayr K., Blazek D., Anand K., Fisher R.P., Eick D., Geyer M.;
RT   "The structure and substrate specificity of human Cdk12/Cyclin K.";
RL   Nat. Commun. 5:3505-3505(2014).
RN   [27]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-530; HIS-912; GLN-1189 AND LEU-1275.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Cyclin-dependent kinase that phosphorylates the C-terminal
CC       domain (CTD) of the large subunit of RNA polymerase II (POLR2A),
CC       thereby acting as a key regulator of transcription elongation.
CC       Regulates the expression of genes involved in DNA repair and is
CC       required for the maintenance of genomic stability. Preferentially
CC       phosphorylates 'Ser-5' in CTD repeats that are already phosphorylated
CC       at 'Ser-7', but can also phosphorylate 'Ser-2'. Required for RNA
CC       splicing, possibly by phosphorylating SRSF1/SF2. Involved in regulation
CC       of MAP kinase activity, possibly leading to affect the response to
CC       estrogen inhibitors. {ECO:0000269|PubMed:11683387,
CC       ECO:0000269|PubMed:19651820, ECO:0000269|PubMed:20952539,
CC       ECO:0000269|PubMed:22012619, ECO:0000269|PubMed:24662513}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[DNA-directed RNA polymerase] + ATP = ADP + H(+) + phospho-
CC         [DNA-directed RNA polymerase]; Xref=Rhea:RHEA:10216, Rhea:RHEA-
CC         COMP:11321, Rhea:RHEA-COMP:11322, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546,
CC         ChEBI:CHEBI:456216; EC=2.7.11.23;
CC         Evidence={ECO:0000305|PubMed:20952539};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.22;
CC   -!- ACTIVITY REGULATION: Inhibited by the ATP analog flavopiridol,
CC       purvalanol A, purvalanol B, staurosporine and CR8.
CC       {ECO:0000269|PubMed:24662513}.
CC   -!- SUBUNIT: Interacts with CCNL1 and CCNL2 (By similarity). Interacts with
CC       CCNK. {ECO:0000250, ECO:0000269|PubMed:22012619,
CC       ECO:0000269|PubMed:24662513}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 1
CC       (HHV-1) transcriptional regulator ICP22. {ECO:0000269|PubMed:34696162}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11683387}. Nucleus
CC       speckle {ECO:0000269|PubMed:11683387}. Note=Colocalized with nuclear
CC       speckles throughout interphase. {ECO:0000269|PubMed:11683387}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NYV4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NYV4-2; Sequence=VSP_030284;
CC       Name=3;
CC         IsoId=Q9NYV4-3; Sequence=VSP_040908, VSP_040909, VSP_040910;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:11683387}.
CC   -!- PTM: Phosphorylation at Thr-893 increases kinase activity.
CC       {ECO:0000269|PubMed:24662513}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving CDK12 may be a cause
CC       gastric cancer. Deletions within 17q12 region producing fusion
CC       transcripts with ERBB2, leading to CDK12-ERBB2 fusion leading to
CC       trunctated CDK12 protein not in-frame with ERBB2.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA74927.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF227198; AAF36401.1; -; mRNA.
DR   EMBL; AB020711; BAA74927.2; ALT_INIT; mRNA.
DR   EMBL; AK302645; BAG63886.1; -; mRNA.
DR   EMBL; AC009283; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471152; EAW60577.1; -; Genomic_DNA.
DR   EMBL; BC140854; AAI40855.1; -; mRNA.
DR   EMBL; BC150265; AAI50266.1; -; mRNA.
DR   CCDS; CCDS11337.1; -. [Q9NYV4-1]
DR   CCDS; CCDS45666.1; -. [Q9NYV4-2]
DR   RefSeq; NP_055898.1; NM_015083.2. [Q9NYV4-2]
DR   RefSeq; NP_057591.2; NM_016507.3. [Q9NYV4-1]
DR   PDB; 4CXA; X-ray; 3.15 A; A/C=715-1052.
DR   PDB; 4NST; X-ray; 2.20 A; A/C=714-1063.
DR   PDB; 4UN0; X-ray; 3.15 A; C/D=715-1038.
DR   PDB; 5ACB; X-ray; 2.70 A; C/D=715-1052.
DR   PDB; 6B3E; X-ray; 3.06 A; A/C=717-1036.
DR   PDB; 6CKX; X-ray; 2.80 A; A/C=714-1063.
DR   PDB; 6TD3; X-ray; 3.46 A; B/E/H=712-1051.
DR   PDB; 7NXK; X-ray; 3.00 A; A/C=714-1063.
DR   PDBsum; 4CXA; -.
DR   PDBsum; 4NST; -.
DR   PDBsum; 4UN0; -.
DR   PDBsum; 5ACB; -.
DR   PDBsum; 6B3E; -.
DR   PDBsum; 6CKX; -.
DR   PDBsum; 6TD3; -.
DR   PDBsum; 7NXK; -.
DR   AlphaFoldDB; Q9NYV4; -.
DR   SMR; Q9NYV4; -.
DR   BioGRID; 119715; 221.
DR   ComplexPortal; CPX-241; Cyclin K-CDK12 complex.
DR   CORUM; Q9NYV4; -.
DR   DIP; DIP-39768N; -.
DR   IntAct; Q9NYV4; 32.
DR   MINT; Q9NYV4; -.
DR   STRING; 9606.ENSP00000398880; -.
DR   BindingDB; Q9NYV4; -.
DR   ChEMBL; CHEMBL3559692; -.
DR   GuidetoPHARMACOLOGY; 1965; -.
DR   CarbonylDB; Q9NYV4; -.
DR   GlyConnect; 2877; 1 O-GlcNAc glycan (2 sites).
DR   GlyGen; Q9NYV4; 6 sites, 1 O-linked glycan (6 sites).
DR   iPTMnet; Q9NYV4; -.
DR   PhosphoSitePlus; Q9NYV4; -.
DR   BioMuta; CDK12; -.
DR   DMDM; 308153421; -.
DR   EPD; Q9NYV4; -.
DR   jPOST; Q9NYV4; -.
DR   MassIVE; Q9NYV4; -.
DR   MaxQB; Q9NYV4; -.
DR   PaxDb; Q9NYV4; -.
DR   PeptideAtlas; Q9NYV4; -.
DR   PRIDE; Q9NYV4; -.
DR   ProteomicsDB; 83279; -. [Q9NYV4-1]
DR   ProteomicsDB; 83280; -. [Q9NYV4-2]
DR   ProteomicsDB; 83281; -. [Q9NYV4-3]
DR   Antibodypedia; 2096; 242 antibodies from 31 providers.
DR   DNASU; 51755; -.
DR   Ensembl; ENST00000430627.6; ENSP00000407720.2; ENSG00000167258.15. [Q9NYV4-2]
DR   Ensembl; ENST00000447079.6; ENSP00000398880.4; ENSG00000167258.15. [Q9NYV4-1]
DR   GeneID; 51755; -.
DR   KEGG; hsa:51755; -.
DR   MANE-Select; ENST00000447079.6; ENSP00000398880.4; NM_016507.4; NP_057591.2.
DR   UCSC; uc002hrw.6; human. [Q9NYV4-1]
DR   CTD; 51755; -.
DR   DisGeNET; 51755; -.
DR   GeneCards; CDK12; -.
DR   HGNC; HGNC:24224; CDK12.
DR   HPA; ENSG00000167258; Low tissue specificity.
DR   MIM; 615514; gene.
DR   neXtProt; NX_Q9NYV4; -.
DR   OpenTargets; ENSG00000167258; -.
DR   PharmGKB; PA165431656; -.
DR   VEuPathDB; HostDB:ENSG00000167258; -.
DR   eggNOG; KOG0600; Eukaryota.
DR   GeneTree; ENSGT00940000157595; -.
DR   InParanoid; Q9NYV4; -.
DR   OMA; STKHNRE; -.
DR   OrthoDB; 925637at2759; -.
DR   PhylomeDB; Q9NYV4; -.
DR   TreeFam; TF101060; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   BRENDA; 2.7.11.23; 2681.
DR   PathwayCommons; Q9NYV4; -.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   SignaLink; Q9NYV4; -.
DR   SIGNOR; Q9NYV4; -.
DR   BioGRID-ORCS; 51755; 318 hits in 1118 CRISPR screens.
DR   ChiTaRS; CDK12; human.
DR   GeneWiki; CRKRS; -.
DR   GenomeRNAi; 51755; -.
DR   Pharos; Q9NYV4; Tchem.
DR   PRO; PR:Q9NYV4; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9NYV4; protein.
DR   Bgee; ENSG00000167258; Expressed in buccal mucosa cell and 173 other tissues.
DR   ExpressionAtlas; Q9NYV4; baseline and differential.
DR   Genevisible; Q9NYV4; HS.
DR   GO; GO:0002944; C:cyclin K-CDK12 complex; IPI:MGI.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IBA:GO_Central.
DR   GO; GO:0008024; C:cyclin/CDK positive transcription elongation factor complex; IBA:GO_Central.
DR   GO; GO:0019908; C:nuclear cyclin-dependent protein kinase holoenzyme complex; ISS:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0030332; F:cyclin binding; IPI:MGI.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; IDA:HGNC-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IDA:GO_Central.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0070816; P:phosphorylation of RNA polymerase II C-terminal domain; IDA:ComplexPortal.
DR   GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:HGNC-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0043405; P:regulation of MAP kinase activity; IMP:UniProtKB.
DR   GO; GO:0043484; P:regulation of RNA splicing; IEA:Ensembl.
DR   GO; GO:0008380; P:RNA splicing; ISS:UniProtKB.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IDA:GO_Central.
DR   GO; GO:0006368; P:transcription elongation by RNA polymerase II promoter; IBA:GO_Central.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Chromosomal rearrangement;
KW   Host-virus interaction; Isopeptide bond; Kinase; mRNA processing;
KW   mRNA splicing; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   CHAIN           1..1490
FT                   /note="Cyclin-dependent kinase 12"
FT                   /id="PRO_0000085715"
FT   DOMAIN          727..1020
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..703
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1047..1098
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1161..1189
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1220..1348
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1441..1460
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1466..1490
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        17..33
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        36..50
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        85..105
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        106..121
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        122..139
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        149..163
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        173..194
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        233..364
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        365..379
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        398..412
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        432..456
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        462..476
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        477..523
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        528..572
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        573..621
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        640..665
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        675..695
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1066..1081
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1220..1243
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1259..1284
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1333..1348
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        859
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         733..741
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         756
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         814..819
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         1040
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         57
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         73
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         236
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         249
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         265
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         274
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         276
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         303
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         310
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         312
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         318
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         323
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         332
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         341
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         343
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         345
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         385
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231"
FT   MOD_RES         400
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231"
FT   MOD_RES         420
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         423
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         514
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         614
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         644
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3MJK5"
FT   MOD_RES         681
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         685
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         692
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         889
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         893
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:24662513,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1053
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1083
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1244
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1246
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14AX6"
FT   CROSSLNK        263
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        509
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        655
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         349
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_040908"
FT   VAR_SEQ         1205..1274
FT                   /note="DMQNILAVLLSQLMKTQEPAGSLEENNSDKNSGPQGPRRTPTMPQEEAAACP
FT                   PHILPPEKRPPEPPGPPP -> ILWYMQRPNCKTMGSWGQEPLGPAAQEQAFTGGAQLS
FT                   LLLMENSIGGLQESHQEGEEGEEFLTNPETSVS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_040909"
FT   VAR_SEQ         1254..1262
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10048485,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_030284"
FT   VAR_SEQ         1275..1490
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_040910"
FT   VARIANT         530
FT                   /note="P -> A (in dbSNP:rs56121596)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041968"
FT   VARIANT         912
FT                   /note="R -> H (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041969"
FT   VARIANT         1189
FT                   /note="L -> Q (in dbSNP:rs56362165)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041970"
FT   VARIANT         1275
FT                   /note="P -> L (in dbSNP:rs34070318)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041971"
FT   MUTAGEN         877
FT                   /note="D->N: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:24662513"
FT   CONFLICT        133
FT                   /note="S -> G (in Ref. 4; BAG63886)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        268
FT                   /note="S -> G (in Ref. 4; BAG63886)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        639
FT                   /note="D -> G (in Ref. 1; AAF36401)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        737
FT                   /note="T -> I (in Ref. 4; BAG63886)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        745
FT                   /note="K -> R (in Ref. 1; AAF36401)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        822
FT                   /note="G -> V (in Ref. 4; BAG63886)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1195
FT                   /note="T -> M (in Ref. 1; AAF36401, 2; BAA74927 and 6;
FT                   AAI50266)"
FT                   /evidence="ECO:0000305"
FT   HELIX           724..726
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          727..735
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          737..746
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   TURN            747..749
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          752..758
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          761..763
FT                   /evidence="ECO:0007829|PDB:5ACB"
FT   STRAND          764..767
FT                   /evidence="ECO:0007829|PDB:6CKX"
FT   HELIX           769..778
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          789..794
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   TURN            802..804
FT                   /evidence="ECO:0007829|PDB:5ACB"
FT   STRAND          809..814
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          817..819
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           820..826
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           833..852
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           862..864
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          865..867
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          873..875
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           878..880
FT                   /evidence="ECO:0007829|PDB:6TD3"
FT   STRAND          886..888
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           899..901
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           904..907
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           916..931
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           941..952
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   TURN            957..959
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           961..965
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   TURN            967..971
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           982..985
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   TURN            986..988
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           991..1000
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   TURN            1005..1007
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           1011..1014
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           1018..1021
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           1025..1027
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   STRAND          1035..1037
FT                   /evidence="ECO:0007829|PDB:4NST"
FT   HELIX           1041..1045
FT                   /evidence="ECO:0007829|PDB:4NST"
SQ   SEQUENCE   1490 AA;  164155 MW;  D6B04B998ECDE58E CRC64;
     MPNSERHGGK KDGSGGASGT LQPSSGGGSS NSRERHRLVS KHKRHKSKHS KDMGLVTPEA
     ASLGTVIKPL VEYDDISSDS DTFSDDMAFK LDRRENDERR GSDRSDRLHK HRHHQHRRSR
     DLLKAKQTEK EKSQEVSSKS GSMKDRISGS SKRSNEETDD YGKAQVAKSS SKESRSSKLH
     KEKTRKEREL KSGHKDRSKS HRKRETPKSY KTVDSPKRRS RSPHRKWSDS SKQDDSPSGA
     SYGQDYDLSP SRSHTSSNYD SYKKSPGSTS RRQSVSPPYK EPSAYQSSTR SPSPYSRRQR
     SVSPYSRRRS SSYERSGSYS GRSPSPYGRR RSSSPFLSKR SLSRSPLPSR KSMKSRSRSP
     AYSRHSSSHS KKKRSSSRSR HSSISPVRLP LNSSLGAELS RKKKERAAAA AAAKMDGKES
     KGSPVFLPRK ENSSVEAKDS GLESKKLPRS VKLEKSAPDT ELVNVTHLNT EVKNSSDTGK
     VKLDENSEKH LVKDLKAQGT RDSKPIALKE EIVTPKETET SEKETPPPLP TIASPPPPLP
     TTTPPPQTPP LPPLPPIPAL PQQPPLPPSQ PAFSQVPASS TSTLPPSTHS KTSAVSSQAN
     SQPPVQVSVK TQVSVTAAIP HLKTSTLPPL PLPPLLPGDD DMDSPKETLP SKPVKKEKEQ
     RTRHLLTDLP LPPELPGGDL SPPDSPEPKA ITPPQQPYKK RPKICCPRYG ERRQTESDWG
     KRCVDKFDII GIIGEGTYGQ VYKAKDKDTG ELVALKKVRL DNEKEGFPIT AIREIKILRQ
     LIHRSVVNMK EIVTDKQDAL DFKKDKGAFY LVFEYMDHDL MGLLESGLVH FSEDHIKSFM
     KQLMEGLEYC HKKNFLHRDI KCSNILLNNS GQIKLADFGL ARLYNSEESR PYTNKVITLW
     YRPPELLLGE ERYTPAIDVW SCGCILGELF TKKPIFQANL ELAQLELISR LCGSPCPAVW
     PDVIKLPYFN TMKPKKQYRR RLREEFSFIP SAALDLLDHM LTLDPSKRCT AEQTLQSDFL
     KDVELSKMAP PDLPHWQDCH ELWSKKRRRQ RQSGVVVEEP PPSKTSRKET TSGTSTEPVK
     NSSPAPPQPA PGKVESGAGD AIGLADITQQ LNQSELAVLL NLLQSQTDLS IPQMAQLLNI
     HSNPEMQQQL EALNQSISAL TEATSQQQDS ETMAPEESLK EAPSAPVILP SAEQTTLEAS
     STPADMQNIL AVLLSQLMKT QEPAGSLEEN NSDKNSGPQG PRRTPTMPQE EAAACPPHIL
     PPEKRPPEPP GPPPPPPPPP LVEGDLSSAP QELNPAVTAA LLQLLSQPEA EPPGHLPHEH
     QALRPMEYST RPRPNRTYGN TDGPETGFSA IDTDERNSGP ALTESLVQTL VKNRTFSGSL
     SHLGESSSYQ GTGSVQFPGD QDLRFARVPL ALHPVVGQPF LKAEGSSNSV VHAETKLQNY
     GELGPGTTGA SSSGAGLHWG GPTQSSAYGK LYRGPTRVPP RGGRGRGVPY
//
